STERIS (NYSE:STE) Releases Earnings Results, Beats Expectations By $0.16 EPS

STERIS (NYSE:STE) posted its quarterly earnings data on Tuesday. The medical equipment provider reported $2.14 EPS for the quarter, topping the consensus estimate of $1.98 by $0.16, RTT News reports. The firm had revenue of $1.28 billion during the quarter, compared to analyst estimates of $1.27 billion. STERIS had a return on equity of 13.89% and a net margin of 7.36%. STERIS’s revenue was down .4% on a year-over-year basis. During the same period in the prior year, the business posted $2.00 EPS. STERIS updated its FY25 guidance to $9.05-$9.25 EPS and its FY 2025 guidance to 9.050-9.250 EPS.

STERIS Stock Performance

NYSE STE traded down $3.70 during trading hours on Friday, reaching $235.98. The stock had a trading volume of 421,762 shares, compared to its average volume of 488,756. The stock has a fifty day moving average of $225.17 and a 200 day moving average of $222.88. The stock has a market cap of $23.33 billion, a P/E ratio of 61.76 and a beta of 0.83. The company has a debt-to-equity ratio of 0.49, a quick ratio of 2.36 and a current ratio of 3.08. STERIS has a 52-week low of $195.47 and a 52-week high of $243.37.

STERIS Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, September 20th. Shareholders of record on Thursday, September 5th will be given a dividend of $0.57 per share. The ex-dividend date of this dividend is Thursday, September 5th. This represents a $2.28 dividend on an annualized basis and a yield of 0.97%. This is a boost from STERIS’s previous quarterly dividend of $0.52. STERIS’s payout ratio is currently 54.45%.

Insider Activity at STERIS

In other STERIS news, SVP Cary L. Majors sold 2,024 shares of the stock in a transaction dated Monday, May 13th. The stock was sold at an average price of $232.13, for a total transaction of $469,831.12. Following the sale, the senior vice president now directly owns 11,369 shares of the company’s stock, valued at approximately $2,639,085.97. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other STERIS news, SVP Cary L. Majors sold 2,024 shares of the company’s stock in a transaction that occurred on Monday, May 13th. The stock was sold at an average price of $232.13, for a total value of $469,831.12. Following the sale, the senior vice president now owns 11,369 shares in the company, valued at approximately $2,639,085.97. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, VP Renato Tamaro sold 1,154 shares of STERIS stock in a transaction that occurred on Thursday, May 16th. The shares were sold at an average price of $231.64, for a total transaction of $267,312.56. Following the transaction, the vice president now directly owns 6,677 shares of the company’s stock, valued at $1,546,660.28. The disclosure for this sale can be found here. Insiders sold 7,762 shares of company stock worth $1,798,477 over the last three months. Company insiders own 1.14% of the company’s stock.

Analysts Set New Price Targets

STE has been the subject of several research reports. StockNews.com downgraded shares of STERIS from a “buy” rating to a “hold” rating in a report on Monday. Piper Sandler reaffirmed a “neutral” rating and set a $225.00 target price (up from $220.00) on shares of STERIS in a research report on Friday, May 10th. JMP Securities reaffirmed a “market outperform” rating and issued a $265.00 price target on shares of STERIS in a research report on Wednesday. Stephens reaffirmed an “overweight” rating and issued a $260.00 price objective on shares of STERIS in a research report on Wednesday. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of STERIS in a research report on Thursday. Four investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $243.60.

STERIS Company Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.